The UCSF-GIVI CFAR Virology Core Laboratory provides laboratory services, consultation and training formultidisciplinary, translational research in order to advance collaborators' research programs in theprevention, treatment and understanding of HIV/AIDS. The laboratory typically supports 50 studies annually,ranging from small investigational pilot studies to large, multi-center clinical trials. Collectively, this work hassignificantly broadened our understanding of HIV disease pathogenesis, transmission and treatment.
The specific aims of the laboratory are to provide:1. Service through development and implementation of molecular diagnostic assays and analysis toolsunder strict adherence to rigorous operational procedures and quality assurance programs.2. Research through scientific leadership and laboratory resources to advance our understanding of HIV-1 transmission and correlates of protection that may lead to novel strategies for prevention. Viral replication in the context of latency and partial ARV drug suppression. The causes and consequences of ARV drug resistance. Host factors that modulate HIV replication and evolution. HIV replication and evolution in tissue compartments with a focus on transmission, antiretroviraldrug resistance and disease progression.3. Education and outreach through Mentoring and training of junior investigators and research scientists focused on translationalresearch in local, national and international settings. Consultation with research collaborators, junior scientists and community members to assist inthe interpretation and comprehension of virologic research findings.By collaborating with an increasingly strong network of multidisciplinary basic and clinical scientists, theVirology Core Laboratory is strategically and operationally poised to leverage CFAR funding to effectivelysupport translational research, and advance our understanding of HIV transmission and diseasepathogenesis, identify new and optimize the use of existing antiviral agents, and to guide vaccine design.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027763-16
Application #
7278983
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Project Start
2007-07-01
Project End
2012-08-31
Budget Start
2007-07-01
Budget End
2008-08-31
Support Year
16
Fiscal Year
2007
Total Cost
$232,508
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Pulugulla, Sree H; Packard, Thomas A; Galloway, Nicole L K et al. (2018) Distinct mechanisms regulate IL1B gene transcription in lymphoid CD4 T cells and monocytes. Cytokine 111:373-381
Mohamed, Tamer M A; Ang, Yen-Sin; Radzinsky, Ethan et al. (2018) Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration. Cell 173:104-116.e12
Chammartin, Frédérique; Zürcher, Kathrin; Keiser, Olivia et al. (2018) Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis. Clin Infect Dis 67:1643-1652
Vardi, Noam; Chaturvedi, Sonali; Weinberger, Leor S (2018) Feedback-mediated signal conversion promotes viral fitness. Proc Natl Acad Sci U S A 115:E8803-E8810
Carrico, Adam W; Flentje, Annesa; Kober, Kord et al. (2018) Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. Brain Behav Immun 71:108-115
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Sauceda, John A; Lisha, Nadra E; Neilands, Torsten B et al. (2018) Cognitive-affective depressive symptoms and substance use among Latino and non-Latino White patients in HIV care: an analysis of the CFAR network of integrated clinical systems cohort. J Behav Med :
Carrico, Adam W; Cherenack, Emily M; Roach, Margaret E et al. (2018) Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. AIDS 32:767-771
Tymejczyk, Olga; Brazier, Ellen; Yiannoutsos, Constantin et al. (2018) HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Med 15:e1002534
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912

Showing the most recent 10 out of 1541 publications